唑来膦酸联合骨化三醇对因骨质疏松性股骨颈骨折行全髋关节置换或半髋关节置换的老年患者的疗效
这项前瞻性研究纳入95例2015年8月至2018年6月因骨质疏松性股骨颈骨折行全髋关节置换或半髋关节置换的老年患者,随机分为唑来膦酸组和对照组。唑来膦酸组在术前2天接受每年单次5 mg唑来膦酸静脉注射联合0.5 μg/日骨化三醇和1000 mg/日碳酸钙,对照组仅用相同剂量骨化三醇和碳酸钙。结果显示唑来膦酸组术后6和12个月骨密度显著高于对照组,骨代谢标志物P1NP和β-CTX在治疗6个月时保持较低水平,但两组Harris髋关节评分及关节功能优良率无显著差异,且唑来膦酸组不良事件发生率显著更高。
要点
- 唑来膦酸组术后6和12个月骨密度显著高于对照组。
- 治疗6个月时唑来膦酸组P1NP和β-CTX较对照组保持在较低水平。
- 两组Harris髋关节评分均值及关节功能优良率随访期间无显著差异。
核心结论
- 单次输注唑来膦酸在改善股骨颈健侧、腰椎和全髋骨密度及降低骨代谢标志物水平方面显示出前景,可能改善接受全髋关节置换或半髋关节置换的骨质疏松性股骨颈骨折患者的临床结局。
研究设计与样本
- 前瞻性研究,纳入2015年8月至2018年6月期间接受全髋关节置换或半髋关节置换的95例老年股骨颈骨折患者,随机分为唑来膦酸组和对照组。
主要发现
- 唑来膦酸组骨密度在随访期间得到改善,且术后6和12个月显著高于对照组。
- 治疗6个月后,唑来膦酸组骨代谢标志物P1NP和β-CTX与对照组相比保持在相对较低水平。
- 随访期间两组Harris髋关节评分均值及关节功能优良率无显著差异。
- 唑来膦酸组不良事件发生率显著高于对照组。
关键数值与推荐
- 唑来膦酸组在术前2天接受每年单次5 mg唑来膦酸静脉注射,联合0.5 μg/日骨化三醇和1000 mg/日碳酸钙。
- 对照组仅接受相同剂量的骨化三醇和碳酸钙,不使用唑来膦酸。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Zoledronic acid could improve the clinical outcome in elderly patients receiving total hip arthroplasty or hemiarthroplasty for osteoporotic femoral neck fracture in the 1-year prospective study. INTRODUCTION: To validate the therapeutic efficacy of zoledronic acid (ZOL) in elderly patients with femoral neck fracture who received total hip arthroplasty (THA) or hemiarthroplasty (HA). METHODS: Included in this study were 95 elderly patients with femoral neck fractures who received THA/HA between August 2015 and June 2018. They were randomized into a ZOL group and a control group. Patients in ZOL group received a yearly single dose of 5 mg ZOL intravenous injection plus 0.5 μg/day calcitriol and 1000 mg/day calcium carbonate 2 days before THA or HA. Patients in the control group were treated with the same dose of calcitriol and calcium carbonate only without ZOL. Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry. Bone metabolism markers including the total extension of the peptide type I collagen amino end (P1NP) and beta collagen degradation product (β-CTX) were obtained by serum examination. The postoperative functional outcome was assessed using Harris Hip Score (HHS). RESULTS: During the follow-up period, BMD in the ZOL group was improved and significantly higher than that in the control group at 6 and 12 months post-operation. Bone metabolism markers P1NP and β-CTX in ZOL group remained at a relatively low level as compared with that in the control group at 6 months after treatment. No significant difference in the mean HHS and the excellent/good rate of joint function was observed during the follow-up period between the two groups. The occurrence of adverse events in the ZOL group was significantly higher than that in the control group. CONCLUSIONS: A single infusion of ZOL shows promise in improving BMD of the healthy side of the femoral neck, lumbar spine, and total hip and decreasing the level of bone markers, which may improve the clinical outcome of patients with osteoporotic femoral neck fractures receiving THA/HA.
引用
- Zhu K, Zhang J, Zhang C, et al. Therapeutic efficacy of zoledronic acid combined with calcitriol in elderly patients receiving total hip arthroplasty or hemiarthroplasty for osteoporotic femoral neck fracture. Osteoporos Int. 2020. PMID: 32989470. doi:10.1007/s00198-020-05637-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。